Results for CAR T-Cell Therapy

Dr. Myers aims to improve outcomes for children and young adults receiving cellular immunotherapies for high-risk hematologic toxicities. Her current research is focused on studying toxicities of CAR T-cell therapies through a combination of clinical epidemiologic and translational research methods.

Dr. Laetsch is a pediatric oncologist who provides clinical care and conducts research with the overarching goal of improving treatment options for children with difficult to treat cancers.

Dr. Richman's research focuses on chimeric antigen receptor (CAR) T cells targeting solid tumors with the goal of translating these findings to this unmet clinical need.

Dr. Schofield's research focuses on neurocognitive outcomes of oncology treatment. Her areas of interest are acute and long-term neurotoxicities and cognitive sequelae of cellular therapy, including hematopoietic stem cell transplant and chimeric antigen receptor (CAR) T-cell therapy.

Dr. Leahy studies the use of patient-reported outcomes (PROs) for symptom monitoring in pediatric oncology and how they can improve clinical outcomes. She is also interested in how PROs can be leveraged to inform predictive models for novel therapeutics, such as CAR T-cell therapy.